Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies. Infections have been reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer patients treated with these agents. METHODS: Pubmed and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kaymakcalan, M D, Je, Y, Sonpavde, G, Galsky, M, Nguyen, P L, Heng, D Y C, Richards, C J, Choueiri, T K
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3694254/
https://ncbi.nlm.nih.gov/pubmed/23736025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.278
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars